By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis

Oncotarget

Volumn 6, Issue 29, 2015, Pages 27187-27198

  Gao, Jiujiao ^a   Liu, Xue ^a   Yang, Fan ^a   Liu, Tingjiao ^a   Yan, Qiu ^a   Yang, Xuesong ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; EpCAM; Metastasis; MMP 9; Ras Raf ERK

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN; SMALL INTERFERING RNA; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; MATRIX METALLOPROTEINASE INHIBITOR; MMP9 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST METASTASIS; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL; TUMOR INVASION; UPREGULATION; ADULT; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL MOTION; CHEMISTRY; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; IMMUNOHISTOCHEMISTRY; MCF-7 CELL LINE; METABOLISM; METASTASIS; MIDDLE AGED; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADULT; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL CELL ADHESION MOLECULE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MCF-7 CELLS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; RAF KINASES; RAS PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84944474633     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4551     Document Type: Article

References (34)

1. Alphandery E. Perspectives of breast cancer thermotherapies. J Cancer. 2014; 5:472-9.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10-29.
3. Karabulut S, Tas F, Tastekin D, Karabulut M, Yasasever CT, Ciftci R, et al. The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer. Tumour Biol. 2014; 35:8849-8860.
4. Xu M, Qian G, Xie F, Shi C, Yan L, Yu L, et al. Expression of epithelial cell adhesion molecule associated with elevated ductular reactions in hepatocellar carcinoma. Clin Res Hepatol Gastroenterol. 2014; 38:699-705.
5. Chen X, Ma WY, Xu SC, Liang Y, Fu YB, Pang B, et al. The overexpression of Epithelial cell adhesion molecule (EpCAM) in glioma. J Neurooncol. 2014; 119:39-47.
6. Goossens-Beumer IJ, Zeestraten EC, Benard A, Christen T, Reimers MS, Keijzer R, et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer 2014; 110:2935-44.
7. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013; 57:1458-68.
8. Fong D, Moser P, Kasal A, Seeber A, Gastl G, Martowicz A, et al. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. Histopathology. 2013; 64:683-92.
9. Wang YY, Li L, Zhao ZS, Wang YX, Ye ZY, Tao HQ. L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients. J Exp Clin Cancer Res. 2014; 32:66.
10. Kroepil F, Dulian A, Vallbohmer D, Geddert H, Krieg A, Vay C, et al. High EpCAM expression is linked to proliferation and lauren classification in gastric cancer. BMC Res Notes 2013; 6:253.
11. Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol 2013; 45:2736-48.
12. Beta M, Khetan V, Chatterjee N, Suganeswari G, Rishi P, Biswas J, et al. EpCAM Knockdown Alters MicroRNA Expression in Retinoblastoma- Functional. PLoS One. 2014; 9:e114800. LID - 10.1371/journal.pone.0114800 [doi].
13. Shen CI, Lee HC, Kao YH, Wu CS, Chen PH, Lin SZ, Lai PS, Su HL, et al. EpCAM induction functionally links to the Wnt-enhanced cell proliferation in. Cell Transplant 2014;23:1031-44 LID - 10.3727/096368913X666403 [doi].
14. Gires O, Bauerle PA. EpCAM as a target in cancer therapy. J Clin Oncol. 2012; 28:e239-40; author reply e241-2.
15. Agboola AJ, Paish EC, Rakha EA, Powe DG, Macmillan RD, Ellis IO, et al. EpCAM expression is an indicator of recurrence in basal-like breast cancer. Breast Cancer Res Treat. 2012; 133:575-82.
16. Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011; 64:415-20.
17. Soussi T, Wiman KG. TP53: an oncogene in disguise. Cell Death Differ. 2015; 29: doi: 10.1038.
18. Vernet-Tomas M, Banos N, Sabadell D, Corominas JM, Mestre-Fusco A, Suarez-Pinera M, et al. p53 expression in breast cancer predicts tumors with low probability of non-sentinel nodes infiltration. J Obstet Gynaecol Res. 2015; 6: doi: 10.1111.
19. Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol. 2013; 66:512-6.
20. Khoi PN, Park JS, Kim JH, Xia Y, Kim NH, Kim KK, Jung YD, et al. (-)-Epigallocatechin-3-gallate blocks nicotine- induced matrix metalloproteinase-9. Int J Oncol 2013; 43:868-76 LID - 10.3892/ijo.2013.2006 [doi].
21. Kim JH, Kim JH, Kim SC, Yi YS, Yang WS, Yang Y, Kim HG, Lee JY, Kim KH, Yoo BC, Hong S, Cho JY, et al. Adenosine dialdehyde suppresses MMP-9-mediated invasion of cancer cells by. Biochem Pharmacol 2013; 86:1285-300 LID - 10.1016/j.bcp.2013.08.022 [doi] LID - S0006-2952(13)00508-X [pii].
22. Zhao Y, Zhu CD, Yan B, Zhao JL, Wang ZH. miRNA-directed regulation of VEGF in tilapia under hypoxia condition. Biochem Biophys Res Commun 2014; 454:183-188. LID - S0006-291X(14)01877-4 [pii] LID - 10.1016/j.bbrc.2014.10.068 [doi].
23. Imrich S, Hachmeister M, Gires O. EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr 2012;6:30-8 LID - 10.4161/cam.18953 [doi].
24. Ligtenberg MJ, Kuiper RP, Geurts van Kessel A, Hoogerbrugge N. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam Cancer. 2013; 12:169-74. LID - 10.1007/s10689-0-9591-x [doi].
25. Ni J, Cozzi PJ, Duan W, Shigdar S, Graham PH, John KH, Li Y, et al. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev. 2012; 31:779-91. LID - 10.1007/s10555-012-9389-1 [doi].
26. Schnell U, Cirulli V, Giepmans BN. EpCAM: structure and function in health and disease. Biochim Biophys Acta. 2013; 1828:1989-2001. LID - 10.1016/j.bbamem.2013.04.018 [doi] LID - S0005-2736(13)00133-8 [pii].
27. Soysal SD, Muenst S, Barbie T, Fleming T, Gao F, Spizzo G, Oertli D, Viehl CT, Obermann EC, Gillanders WE, et al. EpCAM expression varies significantly and is differentially associated with. Br J Cancer. 2013; 108:1480-7. LID - 10.1038/bjc.2013.80 [doi].
28. del Barco Barrantes I, Nebreda AR. Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans. 2012; 40:79-84. LID - 10.1042/BST20110676 [doi].
29. Stupack DG, Cho SY, Klemke RL. Molecular signaling mechanisms of cell migration and invasion. Immunol Res. 2000; 21:83-8.
30. Li H, Zhang K, Liu LH, Ouyang Y, Bu J, Guo HB, Xiao T, et al. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in. Tumour Biol 2014;35:5487-91 LID - 10.1007/s13277-014-1717-3 [doi].
31. Vilen ST, Salo T, Sorsa T, Nyberg P. Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. ScientificWorldJournal. 2013; 2013:920595. LID - 10.1155/2013/920595 [doi].
32. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141:52-67. LID - 10.1016/j. cell.2010.03.015 [doi].
33. Wang AX, Qi XY. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. IUBMB Life. 2013; 65:748-58. LID - 10.1002/iub.1193 [doi].
34. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, et al. Ras/Raf/MEK/ERK and PIK/PTEN/Akt/mTOR cascade inhibitors: how mutations can. Oncotarget. 2012; 3:1068-111.